Maze Therapeutics Announces $150 Million Registered Offering

Rhea-AI Summary

Maze Therapeutics (Nasdaq: MAZE) priced an underwritten registered offering of 5,540,000 common shares at $23.50 per share and offered pre-funded warrants for up to 850,000 shares at $23.499 each. Gross proceeds are expected to be $150 million, before fees.

The offering is expected to close on or about April 23, 2026. Maze intends to use net proceeds to advance R&D for MZE829 (APOL1-mediated kidney disease) and MZE782 (PKU and CKD) and for general corporate purposes. Maze expects cash to fund operations into 2029. Leerink Partners is sole underwriter; several institutional investors are participating.

Positive

• Gross proceeds of $150 million
• Expected funding runway into 2029
• Participation from major institutional investors including Farallon and T. Rowe Price

Negative

• Issuance of 5,540,000 shares plus 850,000 pre-funded warrants (dilutive capital raise)
• Net proceeds will be reduced by underwriting discounts, commissions, and offering expenses

News Market Reaction – MAZE

+3.15%

7 alerts

+3.15% Session close to close

+5.1% Peak in 1 hr 2 min

$1.44B Market Cap

0.8x Rel. Volume

In the Apr 22 session, MAZE gained 3.15%, reflecting a moderate positive market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details a $150 million underwritten offering of common stock and pre-funded warran...

Analysis

This announcement details a $150 million underwritten offering of common stock and pre-funded warrants at $23.50 per share, intended to fund MZE829 and MZE782 development and general corporate needs, with runway guided into 2029. The deal is conducted under an effective Form S-3 shelf and follows earlier reports of positive Phase 2 data and a strengthened balance sheet. Investors may watch execution of trial plans, additional capital raises under the $200,000,000 ATM, and future regulatory milestones.

Key Figures

Common shares offered: 5,540,000 shares Offering price: $23.50 per share Pre-funded warrants: 850,000 warrants +5 more

8 metrics

Common shares offered 5,540,000 shares Underwritten registered common stock offering

Offering price $23.50 per share Price for common stock in registered offering

Pre-funded warrants 850,000 warrants Aggregate shares underlying pre-funded warrants offered

Warrant purchase price $23.499 per pre-funded warrant Purchase price in lieu of common stock

Warrant exercise price $0.001 per share Exercise price for each pre-funded warrant share

Gross proceeds $150 million Expected before underwriting discounts and expenses

Expected closing date April 23, 2026 Anticipated closing of the offering

Runway guidance Into 2029 Funding horizon from net proceeds plus existing cash

Historical Context

5 past events · Latest: Mar 25 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 25	Phase 2 data	Positive	-35.2%	Positive Phase 2 HORIZON topline data for MZE829 in AMKD patients.
Mar 25	Earnings & update	Positive	-35.2%	Q4 and 2025 results plus plans to advance MZE829 and start MZE782 trials.
Feb 25	Conference participation	Neutral	+4.3%	TD Cowen healthcare conference presentation announcement with webcast details.
Feb 04	Conference participation	Neutral	+0.3%	Guggenheim biotech summit presentation announcement and webcast plan.
Jan 05	Conference participation	Neutral	-2.9%	J.P. Morgan Healthcare Conference presentation announcement with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive clinical and financial updates on Mar 25, 2026 led to a sharp -35.24% selloff, showing a pattern of negative price reactions even to favorable news, while neutral conference updates have seen smaller, mixed moves.

Recent Company History

Over the last few months, Maze reported several key milestones. On Mar 25, 2026, positive Phase 2 HORIZON data for MZE829 and earnings with a cash runway into 2028 both coincided with a steep -35.24% reaction. Earlier, participation in major healthcare conferences in Jan–Feb 2026 produced modest price changes. The current offering adds capital to advance MZE829 and MZE782, following earlier disclosures of clinical progress and balance sheet strength in the 10-K and 8-K filings.

Key Terms

pre-funded warrants, underwritten registered offering, shelf registration statement, form s-3, +4 more

8 terms

pre-funded warrants financial

"Maze is offering to certain investors pre-funded warrants to purchase up to..."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

underwritten registered offering financial

"announced the pricing of its underwritten registered offering of 5,540,000 shares..."

An underwritten registered offering is a public sale of a company’s securities that has been officially filed with regulators and is sold through one or more investment banks that agree to buy the securities and resell them to investors. Think of it like a store hiring a wholesaler who guarantees to buy the stock on the shelf so the store can raise cash immediately; for investors it signals structured distribution but can dilute existing shares and affect market price depending on size and demand.

shelf registration statement regulatory

"The public offering is being made pursuant to a shelf registration statement on Form S-3..."

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3 (File No. 333-293206) which became..."

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A prospectus supplement and accompanying prospectus relating to and describing the terms..."

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

apol1-mediated kidney disease (amkd) medical

"including MZE829 for the treatment of APOL1-mediated kidney disease (AMKD)..."

Apol1-mediated kidney disease (AMKD) is kidney damage driven by inherited changes in the APOL1 gene that substantially increase the risk of chronic kidney disease and faster progression to kidney failure, most often seen in people of West African descent. It matters to investors because these genetic drivers define a clear patient subgroup, shaping demand for targeted tests and therapies, influencing clinical trial design and regulatory strategy, and helping estimate market size—like a faulty blueprint that predicts who will need specific medical solutions.

phenylketonuria (pku) medical

"MZE782 for the treatment of phenylketonuria (PKU) and chronic kidney disease..."

A genetic metabolic disorder in which the body cannot break down the amino acid phenylalanine, causing it to build up and potentially damage the brain if untreated; newborn screening and lifelong management are common. Investors care because the condition creates steady demand for diagnostic tests, specialized diets and medical treatments, and because regulatory approvals, reimbursement rules and advances in therapy can materially affect market size and company revenues—think of it like a clogged drain that needs ongoing tools and fixes.

chronic kidney disease (ckd) medical

"MZE782 for the treatment of phenylketonuria (PKU) and chronic kidney disease (CKD)..."

Chronic kidney disease (CKD) is a long-term decline in the kidneys’ ability to filter waste and balance fluids and chemicals in the body, often progressing slowly over months or years; think of it as a filter that gradually becomes clogged and less effective. It matters to investors because CKD drives demand for drugs, dialysis, transplants, diagnostics and related medical devices, influences healthcare costs and reimbursement decisions, and is a common target for clinical trials and regulatory review.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE) today announced the pricing of its underwritten registered offering of 5,540,000 shares of its common stock at a price of $23.50 per share. In addition, and in lieu of common stock, Maze is offering to certain investors pre-funded warrants to purchase up to an aggregate of 850,000 shares of common stock at a purchase price of $23.499 per pre-funded warrant, which represents the per share price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Maze from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Maze, are expected to be $150 million. The offering is expected to close on or about April 23, 2026, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Maze.

The offering includes participation from both new and existing investors including Farallon Capital Management, accounts advised by T. Rowe Price Investment Management, Inc., a large U.S.-based healthcare-focused fund, a leading mutual fund, Frazier Life Sciences, Janus Henderson Investors, Deep Track Capital, and Driehaus Capital Management, as well as other healthcare dedicated funds.

Leerink Partners LLC is acting as sole underwriter for the proposed offering.

Maze currently intends to use any net proceeds from this offering primarily to advance research and development of its product candidates, including MZE829 for the treatment of APOL1-mediated kidney disease (AMKD) and MZE782 for the treatment of phenylketonuria (PKU) and chronic kidney disease (CKD), as well as for general corporate purposes. Maze expects that the net proceeds from this offering, together with its current cash, cash equivalents and marketable securities, will fund operations into 2029 based on its current business plan.

The public offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-293206) which became automatically effective with the Securities and Exchange Commission (“SEC”) on February 4, 2026. A prospectus supplement and accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. A copy of the prospectus supplement relating to the offering, when available, may be obtained from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at 1-800-808-7525 ext. 6105 or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Maze, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Maze Therapeutics, Inc.

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor advancing to Phase 2 with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, but not limited to, statements regarding Maze’s intention to conduct an offering and sale of its securities, the ability to complete the proposed offering and the expected use of proceeds, statements concerning Maze’s future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat CKD, PKU or other indications, the planned timing of Maze’s clinical trials, data results and further development of MZE829, MZE782 and other therapeutics candidates, the ability to drive financial results and stockholder value, and Maze’s expected cash runway. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company’s forward-looking statements due to a variety of factors, including risks and uncertainties related to the company’s ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company’s therapeutic candidates, the timing and results of preclinical studies and clinical trials, the company’s ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company’s business and its financial results are detailed under the heading “Risk Factors” included in the documents the company files from time to time with the SEC, including the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.

Investor Contacts:
Amy Bachrodt, Maze Therapeutics
abachrodt@mazetx.com

Media Contact:
Amanda Lazaro, 1AB Media
Amanda@1ABMedia.com

FAQ

What did Maze Therapeutics (MAZE) announce on April 22, 2026 about a registered offering?

Maze announced a priced underwritten offering to raise gross proceeds of $150 million. According to the company, the sale includes 5,540,000 common shares and pre-funded warrants for up to 850,000 shares at specified prices.

How many shares and pre-funded warrants did MAZE offer and at what price?

Maze offered 5,540,000 common shares at $23.50 per share and pre-funded warrants for 850,000 shares at $23.499. According to the company, the warrant price reflects a $0.001 exercise price per share.

How will the proceeds from the MAZE offering be used and how long will they fund operations?

Maze intends to use net proceeds to advance R&D for MZE829 and MZE782 and for general corporate purposes. According to the company, combined with current cash, proceeds are expected to fund operations into 2029.

Who is underwriting the MAZE offering and which investors are participating?

Leerink Partners LLC is acting as sole underwriter for the offering. According to the company, participants include Farallon Capital, accounts advised by T. Rowe Price, Frazier Life Sciences, Janus Henderson, and other healthcare funds.

When is the MAZE offering expected to close and what conditions apply?

The offering is expected to close on or about April 23, 2026, subject to customary closing conditions. According to the company, completion depends on satisfying standard offering and regulatory conditions.

What does the MAZE offering mean for existing shareholders in terms of dilution?

The offering will increase outstanding securities through 5,540,000 shares and 850,000 pre-funded warrants, causing dilution to existing holders. According to the company, all securities are being offered by Maze under the shelf registration.